News Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
194.4 ^USD	+2.03%		-1.92%	-24.88%

Apr. 19	Needham Adjusts Price Target on Biogen to $294 From $300	MT
Apr. 19	BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Adjusts Price Target on Biogen to $294 From $300	Apr. 19	MT
BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept	Apr. 19	MT
Oppenheimer Adjusts Biogen Price Target to $270 From $290	Apr. 19	MT
UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating	Apr. 17	MT
Wedbush Cuts Biogen's Price Target to $213 From $245	Apr. 17	MT
Argus Adjusts Biogen's Price Target to $240 From $315	Apr. 15	MT
Goldman Sachs Cuts Biogen's Price Target to $393 From $400	Apr. 15	MT
JPMorgan Cuts Biogen's Price Target to $240 From $270, Maintains Neutral Rating	Apr. 11	MT
Morgan Stanley Trims Price Target on Biogen to $339 From $346, Keeps Overweight Rating	Apr. 09	MT
Barclays Cuts Price Target on Biogen to $215 From $230, Maintains Equalweight Rating	Apr. 04	MT
Sector Update: Health Care Stocks Higher Prebell Monday	Apr. 01	MT
Sector Update: Health Care	Apr. 01	MT
Biogen Partner Eisai Submits Supplemental Biologics License Application for Leqembi to FDA	Apr. 01	MT
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	PR
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell	Mar. 25	MT
Biogen : Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application	Mar. 22	PU
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 21	BU
InvestorBrandMedia: Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth	Mar. 20	AQ
BIOGEN : Jefferies confirms its Buy rating on the stock	Mar. 19	CF
Transcript : Biogen Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-19-2024 10:00 AM	Mar. 19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biogen Inc.

Equities

BIIB

US09062X1037

Summary

Filters